InMed Pharmaceuticals Inc. (INM)
Company Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.
The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.
The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.
The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases.
In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Country | Canada |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Eric A. Adams B.S. Chem., M.I.B. |
Contact Details
Address: Suite 310, 815 W. Hastings Street Vancouver, A1 V6C 1B4 British Columbia, Canada | |
Phone | (604) 669-7207 |
Website | inmedpharma.com |
Stock Details
Ticker Symbol | INM |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001728328 |
CUSIP Number | 457637601 |
ISIN Number | CA4576376012 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Eric A. Adams B.S. Chem., M.I.B. | President, Chief Executive Officer and Director |
Michael Woudenberg P.Eng. | Chief Operating Officer |
Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical and Regulatory Affairs |
Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder |
N. Netta Jagpal | Chief Financial Officer and Corporate Secretary |
Sarah Li CPA, CGA | Vice President of Accounting and Controller |
Colin Clancy | Senior Director of Investor Relations |
Jerry P. Griffin | Vice President of Sales and Marketing |
Dr. Eric Chih-Hsien Hsu | Senior Vice President of Preclinical Research and Development |
Dr. Shane A. Johnson Ph.D. | Senior Vice President and GM of BayMedica |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | 8-K | Current Report |
Feb 13, 2024 | 10-Q | Quarterly Report |
Feb 9, 2024 | 8-K | Current Report |
Jan 19, 2024 | 8-K | Current Report |
Jan 16, 2024 | 8-K | Current Report |
Jan 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Dec 22, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
Dec 21, 2023 | 10-K/A | [Amend] Annual report |